Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) has announced the appointment of Dave Jenkins as chief financial officer.
Jenkins has more than 35 years of experience in accounting and finance including 31 years at PricewaterhouseCoopers (PwC), one of the world’s largest accounting and consulting firms.
At PwC, Bioasis said Jenkins was an audit partner, serving multinational public companies, private equity portfolio companies, and venture-backed growth companies. He served companies in multiple sectors including bioscience, software, and healthcare.
READ: Bioasis Technologies partners with Oxyrane to evaluate combining brain therapy technologies
He has deep experience assisting companies to raise capital, develop teams, evaluate and complete acquisitions, design well-controlled systems, and expand internationally.
Bioasis said Jenkins currently has his own advisory practice, Forest View Consulting LLC, where he assists high growth technology and bioscience companies develop strategic business models, enhance business development, and evaluate key transactions
“On behalf of our Board of Directors and our management team, it is my pleasure to welcome Dave to Bioasis," said Deborah Rathjen, Bioasis’ executive chair, in a statement.
"Dave has a proven track record in finance and accounting, including financing transactions, business development, strategic planning, and guiding companies through significant growth. His contributions will be critical as we continue to execute on our mission to advance our internal pipeline and license our proprietary xB3 platform technology.”
Bioasis also noted that Jenkins, who replaces Christine Antalik, has previously worked at several technology and life sciences companies and brings diverse financial management experience in executing the strategic and financial plans of emerging companies.
“I am delighted to join Bioasis at a time when the company is preparing to reach major milestones in its development,” Jenkins said. “I am excited by the potential of the Bioasis xB3 platform technology and admire the team’s focus and vision on bringing transformational therapies to patients with brain cancers and neurological diseases. I look forward to contributing to Bioasis’ success and supporting its mission.”
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham